BR0013157A - Composições farmacêuticas e nutricionais contendo ácidos graxos essenciais e agentes de abaixamento da homocisteìna - Google Patents

Composições farmacêuticas e nutricionais contendo ácidos graxos essenciais e agentes de abaixamento da homocisteìna

Info

Publication number
BR0013157A
BR0013157A BR0013157-1A BR0013157A BR0013157A BR 0013157 A BR0013157 A BR 0013157A BR 0013157 A BR0013157 A BR 0013157A BR 0013157 A BR0013157 A BR 0013157A
Authority
BR
Brazil
Prior art keywords
essential fatty
pharmaceutical
lowering agents
compositions containing
fatty acids
Prior art date
Application number
BR0013157-1A
Other languages
English (en)
Inventor
David Frederick Horrobin
Christian Gouaille
Original Assignee
Laxdale Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laxdale Ltd filed Critical Laxdale Ltd
Publication of BR0013157A publication Critical patent/BR0013157A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)

Abstract

Patente de Invenção: "COMPOSIçõES FARMACêUTICAS E NUTRICIONAIS CONTENDO áCIDOS GRAXOS ESSENCIAIS E AGENTES DE ABAIXAMENTO DA HOMOCISTEìNA". A aplicação combinada de pelo menos um ácido graxo essencial da série n-6 ou n-3, opcionalmente junto com outro(s) ácido(s) graxo(s) essencial(ais) da série n-6 ou n-3, junto com um ou mais agentes de abaixamento de homocisteína. O agente de abaixamento de homocisteína é selecionado entre Vitamina B12, ácido fólico, um composto relacionado a ácido fólico com atividade biológica similar e Vitamina B6.
BR0013157-1A 1999-07-14 2000-07-11 Composições farmacêuticas e nutricionais contendo ácidos graxos essenciais e agentes de abaixamento da homocisteìna BR0013157A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9916536.7A GB9916536D0 (en) 1999-07-14 1999-07-14 Nutritional or pharmaceutical compositions
PCT/GB2000/002681 WO2001003696A1 (en) 1999-07-14 2000-07-11 Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents

Publications (1)

Publication Number Publication Date
BR0013157A true BR0013157A (pt) 2002-04-02

Family

ID=10857244

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0013157-1A BR0013157A (pt) 1999-07-14 2000-07-11 Composições farmacêuticas e nutricionais contendo ácidos graxos essenciais e agentes de abaixamento da homocisteìna

Country Status (24)

Country Link
US (1) US20050147665A1 (pt)
EP (1) EP1200085A1 (pt)
JP (1) JP2003504333A (pt)
KR (1) KR20020025088A (pt)
CN (1) CN1223346C (pt)
AU (1) AU6167800A (pt)
BR (1) BR0013157A (pt)
CA (1) CA2377502A1 (pt)
CZ (1) CZ200258A3 (pt)
EE (1) EE200200021A (pt)
GB (1) GB9916536D0 (pt)
HK (1) HK1042853A1 (pt)
HU (1) HUP0202342A3 (pt)
IL (1) IL147556A0 (pt)
IS (1) IS6205A (pt)
MX (1) MXPA01013210A (pt)
NO (1) NO20020090D0 (pt)
NZ (1) NZ516101A (pt)
PL (1) PL352185A1 (pt)
RU (1) RU2001134300A (pt)
SK (1) SK332002A3 (pt)
TR (1) TR200200045T2 (pt)
WO (1) WO2001003696A1 (pt)
ZA (1) ZA200200259B (pt)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7226916B1 (en) 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
ITMI20010129A1 (it) 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
KR20020069539A (ko) * 2001-02-26 2002-09-05 주식회사 두산 뇌세포 보호용 조성물
KR100427637B1 (ko) * 2001-06-05 2004-04-27 이인규 세포내 에너지 소비 증가제
WO2002102364A1 (fr) * 2001-06-18 2002-12-27 Yamada, Sachiko Preparations medicamenteuses agonistes ppar$g(g)
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
NL1019368C2 (nl) 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
KR100983802B1 (ko) * 2002-06-20 2010-09-27 아스션 더마톨로지 에이/에스 폴리히드록시알칸의 지방산 에스테르 및 피리미딘카르복시 유도체의 신규한 복합체
JP4611622B2 (ja) * 2002-07-11 2011-01-12 第一三共株式会社 血中脂質改善又は血中ホモシステイン低下のための医薬組成物
WO2004006919A1 (ja) * 2002-07-11 2004-01-22 Sankyo Company, Limited 血中脂質改善又は血中ホモシステイン低下のための医薬組成物
US20040132819A1 (en) * 2002-08-06 2004-07-08 Nancy Auestad Appetite control method
EP1551382A4 (en) * 2002-09-27 2007-01-24 Martek Biosciences Corp PROPHYLACTIC TREATMENT WITH DOCOSAHEXAENIC ACID FOR PATIENTS WITH SUBCLINIC INFLAMMATION
KR20040063616A (ko) * 2003-01-08 2004-07-14 김원호 다이어트 식품용 조제
JP2005082523A (ja) * 2003-09-08 2005-03-31 Toru Hasegawa 神経変性疾患特にアルツハイマー病及びパーキンソン病の根本治療薬
JP4522075B2 (ja) * 2003-10-29 2010-08-11 サントリーホールディングス株式会社 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物
ITMI20040069A1 (it) 2004-01-21 2004-04-21 Tiberio Bruzzese Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale
EP1782807B1 (en) * 2004-08-18 2017-08-09 Mochida Pharmaceutical Co., Ltd. Jelly composition
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
US20090149436A1 (en) * 2004-11-16 2009-06-11 Astellas Pharma Inc. Caspase inhibitor
KR20080009075A (ko) * 2005-03-10 2008-01-24 씰 파마, 인크. 영양 제제
US20060217385A1 (en) * 2005-03-10 2006-09-28 Edwards John B Nutritional preparations
JP5967855B2 (ja) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
US20070004639A1 (en) * 2005-07-01 2007-01-04 Bodybio, Inc. Methods and compositions for treating Parkinson's disease
US20090220637A1 (en) 2005-08-26 2009-09-03 Nestec S.A. Nutrition for obese patients
CN101309679B (zh) * 2005-11-11 2013-07-24 持田制药株式会社 胶冻组合物
US8367121B2 (en) * 2005-11-23 2013-02-05 Florida A & M University Nutraceutical agent for attenuating the neurodegenerative process associated with Parkinson's disease
JP5176127B2 (ja) * 2006-01-11 2013-04-03 大正製薬株式会社 視覚機能障害の予防または改善剤
WO2007122613A1 (en) * 2006-04-20 2007-11-01 Technion Research And Development Foundation Ltd. Casein micelles for nanoencapsulation of hydrophobic compounds
JP5300186B2 (ja) * 2006-08-23 2013-09-25 株式会社明治 血中ホモシステイン濃度の上昇を抑制する妊婦用の乳由来組成物
KR100832675B1 (ko) * 2006-09-22 2008-05-26 한상왕 영양 보조제
KR101430214B1 (ko) 2006-12-28 2014-08-18 산토리 홀딩스 가부시키가이샤 신경 재생제
US8343541B2 (en) * 2007-03-15 2013-01-01 Soft Gel Technologies, Inc. Ubiquinol and alpha lipoic acid compositions
WO2008153220A1 (ja) * 2007-06-13 2008-12-18 Suntory Holdings Limited 血管疾患の予防又は治療剤
WO2009002166A1 (en) * 2007-06-26 2008-12-31 N.V. Nutricia Improving memory in subjects with mini-mental state examination of 24-26
WO2009002148A1 (en) * 2007-06-27 2008-12-31 N.V. Nutricia Food composition for prodromal dementia patients
CN104224835A (zh) * 2007-10-25 2014-12-24 营养株式会社 用于降低血中的糖、丙二醛修饰ldl、同型半胱氨酸和/或c反应蛋白的组合物
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
EP2455070A1 (en) * 2008-01-10 2012-05-23 Takeda Pharmaceutical Company Limited Capsule Formulation
ES2862336T3 (es) 2008-09-02 2021-10-07 Amarin Pharmaceuticals Ie Ltd Composición farmacéutica que comprende ácido eicosapentaenoico y ácido nicotínico y métodos de uso de la misma
WO2010053854A1 (en) * 2008-11-06 2010-05-14 Altman Enterprises Llc Medication and treatment for disease
CN106822080A (zh) 2009-04-29 2017-06-13 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
CN102458109B (zh) 2009-04-29 2015-02-11 阿马里纳制药公司 稳定的药物组合物和使用其的方法
SG10201708950XA (en) 2009-06-15 2017-12-28 Ian Osterloh Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
AU2010298222B2 (en) 2009-09-23 2017-01-05 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
CA3162668A1 (en) 2010-02-12 2011-08-18 Gentelon, Inc. Compositions and methods for treating depression
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
WO2012074930A2 (en) 2010-11-29 2012-06-07 Amarin Pharma, Inc. Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US9216209B1 (en) 2011-06-06 2015-12-22 Kilmer S. McCully Compositions and method for utilization of thioretinamide in therapy of degenerative diseases of aging
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2800469B1 (en) 2012-01-06 2021-08-25 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
US9452135B2 (en) 2012-03-20 2016-09-27 Particle Dynamics International, Llc Gelling agent-based dosage form
JP2015522029A (ja) 2012-06-29 2015-08-03 アマリン ファーマシューティカルス アイルランド リミテッド スタチン療法中の患者における心血管系イベントの危険性を減少させる方法
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US9629820B2 (en) 2012-12-24 2017-04-25 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
US10123986B2 (en) 2012-12-24 2018-11-13 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
CN103432156A (zh) * 2013-08-30 2013-12-11 深圳奥萨医药有限公司 ω-3脂肪酸和B族维生素的药物组合物及其用途
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
GB201405033D0 (en) * 2014-03-20 2014-05-07 Isis Innovation Combination therapy
US9655910B2 (en) 2014-03-21 2017-05-23 Bodybio Inc. Compositions and methods for treating addiction
WO2015142501A1 (en) 2014-03-21 2015-09-24 Bodybio Inc. Methods and compositions for treating symptoms of diseases related to imbalance of essential fatty acids
RU2714323C2 (ru) 2014-06-04 2020-02-14 ДиЭс БАЙОФАРМА ЛИМИТЕД Фармацевтические композиции, содержащие дглк, и их применение
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
WO2016205701A1 (en) 2015-06-19 2016-12-22 University Of Southern California Enteral fast access tract platform system
US10631564B2 (en) 2015-06-19 2020-04-28 University Of Southern California Enterically coated microparticle compositions and methods for modified nutrient delivery
CN113214084A (zh) * 2015-11-23 2021-08-06 乐巢拓普有限公司 1,4-二烯体系的位点特异性同位素标记
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018144088A1 (en) 2016-11-03 2018-08-09 Alexander Vuckovic, M.D., Llc Compositions and methods for treating depression
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
CN112218630A (zh) 2018-09-24 2021-01-12 阿马里纳药物爱尔兰有限公司 降低受试者的心血管事件的风险的方法
JP2023514711A (ja) 2020-02-21 2023-04-07 レトロトップ、 インコーポレイテッド 多価不飽和脂肪酸及びその誘導体の同位体修飾方法
WO2022225896A1 (en) 2021-04-21 2022-10-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237118A (en) * 1972-03-06 1980-12-02 Howard Alan N Dietary supplement and dietary methods employing said supplement for the treatment of obesity
GB8719988D0 (en) * 1987-08-25 1987-09-30 Efamol Ltd Chemical compounds
US5895652A (en) * 1996-07-29 1999-04-20 Longevity Institute International Method of metabolic adjuvanation and cellular repair
GB9715203D0 (en) * 1997-07-19 1997-09-24 Piper Edwina M Composition

Also Published As

Publication number Publication date
EP1200085A1 (en) 2002-05-02
GB9916536D0 (en) 1999-09-15
NO20020090L (no) 2002-01-08
CN1223346C (zh) 2005-10-19
JP2003504333A (ja) 2003-02-04
US20050147665A1 (en) 2005-07-07
IL147556A0 (en) 2002-08-14
CA2377502A1 (en) 2001-01-18
HUP0202342A2 (hu) 2002-11-28
PL352185A1 (en) 2003-08-11
ZA200200259B (en) 2002-12-24
SK332002A3 (en) 2002-12-03
EE200200021A (et) 2003-04-15
AU6167800A (en) 2001-01-30
KR20020025088A (ko) 2002-04-03
IS6205A (is) 2001-12-18
RU2001134300A (ru) 2003-08-27
TR200200045T2 (tr) 2002-05-21
NZ516101A (en) 2003-06-30
MXPA01013210A (es) 2004-06-03
CZ200258A3 (cs) 2002-06-12
NO20020090D0 (no) 2002-01-08
WO2001003696A1 (en) 2001-01-18
HK1042853A1 (zh) 2002-08-30
CN1361690A (zh) 2002-07-31
HUP0202342A3 (en) 2003-02-28

Similar Documents

Publication Publication Date Title
BR0013157A (pt) Composições farmacêuticas e nutricionais contendo ácidos graxos essenciais e agentes de abaixamento da homocisteìna
EA200301165A1 (ru) Лекарственное средство на основе оксикодона
BR0112094A (pt) Produtos de confeitaria contendo ingredientes ativos
BR0011433A (pt) Imidazoquinolinas substituìdas com sulfonamida e sulfamida
DE69604653T2 (de) Taxol derivate, deren herstellung und diese enthaltende pharmazeutischen zusammenstellungen
BR9914044A (pt) ésteres tetrahidropirido
DE69319440T2 (de) Herstellung von pharmazeutischen zusammensetzungen, die calcitonin enthalten
PT1318791E (pt) Composicao farmaceutica semi-solida de isotretinoina
FR2840903B1 (fr) Derive de glucose et de vitamine f, compositions le comprenant et utilisations pour ameliorer l'etat des poils et des cheveux
BRPI0417043A (pt) composição farmacêutica, forma de dosagem sólida, método de manufatura de forma de dosagem sólida, e, uso da composição
DE69919179D1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
NL1006764A1 (nl) Bereiding van preparaten die hoge concentraties vitamine B12 bevatten.
FI972308A (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
ATE247953T1 (de) Arzneimittel mit verzögerter wirkstoffabgabe enthaltend isoquercetin und ascorbinsäure
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
FR2711140B1 (fr) 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant.
BR9914644A (pt) Composições tamponadas para diálise
BR0213536A (pt) Formulações de xarope de ribavirina
IT8521322A0 (it) Composti e composizioni farmaceutiche per la terapia di retinopatie e neuropatie diabetiche.
ATE417619T1 (de) Sporopollenin enthaltende lösliche zusammensetzung und verwendung
NO20001812L (no) Gallesyresalter av metaller med fysiologisk virkning, samt terapeutisk anvendelse derav
FR2677250B1 (fr) Compositions pharmaceutiques contenant de l'adenosine-5-triphosphate disodique.
FR2426044A2 (fr) Derives de la vitamine d3 ayant une activite anti-vitamine d
DK1497250T3 (da) Hyperforinderivater, anvendelse heraf og sammensætninger indeholdende disse
IT1296613B1 (it) Farmaco per la cura dell'ircismo contenente un adrenocorticosteroide.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1927 DE 11/12/2007.